



Review

The Genetic Basis of Future Pharmacological Strategies for the Management of Comorbid Obesity and Depression: A Scoping Review

Ravi Philip Rajkumar 

Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research,
Pondicherry 605 006, India; jd0422@jipmer.ac.in; Tel.: +91-413-2296280

Abstract: Depression and obesity are highly comorbid with one another, with evidence of bidirectional causal links between each disorder and a shared biological basis. Genetic factors play a major role in influencing both the occurrence of comorbid depression and obesity, their courses, and their response to existing treatments. The current paper is a scoping review of studies that have evaluated the contribution of specific genetic variants to the comorbidity between obesity and depression. Based on a search of the PubMed and EMBASE databases, 28 studies were included in this review, covering 54 candidate genes. Positive associations were identified for 14 genetic loci (*AKR1C2*, *APOA5*, *COMT*, *DAT1*, *FTO*, *KCNE1*, *MAOA*, *MC4R*, *MCHR2*, *NPY2R*, *NR3C1*, *Ob*, *PCSK9*, and *TAL1*). Replicated findings across two or more independent samples were observed for the *FTO* and *MC4R* genes. Many of these gene products represent novel molecular targets for the pharmacological management of obesity that interact with each other and are not pharmacologically influenced by existing anti-obesity or antidepressant medications. The implications of these associations for future drug development are discussed, with an emphasis on recent evidence on the polygenic architecture of comorbid depression and obesity and on a precision-medicine approach to these conditions.

Keywords: depression; obesity; genetics; leptin; fat-mass- and obesity-associated gene; melanocortin receptor; neuropeptide Y



Citation: Rajkumar, R.P. The Genetic Basis of Future Pharmacological Strategies for the Management of Comorbid Obesity and Depression: A Scoping Review. *Int. J. Transl. Med.* **2023**, *3*, 160–182. <https://doi.org/10.3390/ijtm3010012>

Academic Editor: Pier
Paolo Claudio

Received: 16 February 2023

Revised: 6 March 2023

Accepted: 7 March 2023

Published: 8 March 2023



Copyright: © 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Obesity is the most common metabolic disorder worldwide. According to estimates provided by the World Obesity Federation, around 650 million adults fulfil standard diagnostic criteria for obesity, and the prevalence of this condition has trebled in the past four decades [1]. A recent meta-analysis of global research, covering over 280 studies and 13 million subjects, estimated the global prevalence of central obesity at 41.5%, though there were significant variations related to age, gender, urbanisation, and national income [2]. Though obesity is comorbid with a wide range of medical and psychiatric conditions, comorbidity is not in itself proof of a causal association in either direction [3]. Evidence from cross-sectional and longitudinal research across countries and settings demonstrates a significant bidirectional association between depression and obesity, with each disorder increasing the likelihood of the other by approximately 1.5-fold [4,5]. Analysis of clinical and genetic data supports the contention that the association between depression and obesity is not only bidirectional but also causal: in other words, depression can lead to obesity, and obesity can lead to depression [3,6,7]. This association appears to be specific to obesity and not to less severe increases in body mass [4,5], and remains significant even in individuals without elevations in other physiological parameters, such as plasma glucose, serum cholesterol and triglycerides, blood pressure, or C-reactive protein [8]. A portion of the variance in this association can be explained by behavioural factors, such as overeating in depressed patients, and by the obesogenic effects of medications used in the treatment of depression [7,9]. However, even after taking these factors into account, there

is substantial translational and clinical evidence that obesity and depression are associated with shared alterations in several physiological processes, including dysregulation of the hypothalamic–pituitary–adrenal axis, increased immune–inflammatory activity, changes in the composition of the gut microbiome, and altered brain structure and functioning [10–13].

The management of comorbid obesity and depression is challenging. A recent systematic review concluded that certain psychological and pharmacological therapies showed promise in the management of this group of patients. However, there was insufficient evidence from available studies to provide robust guidance in clinical practice, and the effects of both types of treatment were modest and not well sustained at follow-up [14]. Obesity is associated with a poorer response to antidepressant treatment in depressed patients [15,16], whereas weight loss leads to an improvement in depressive symptoms [17], but this is often difficult to accomplish in practice. Moreover, undiagnosed depression can interfere with motivation for, and adherence to, lifestyle and behavioural interventions for obesity [18]. There is little evidence that currently available antidepressants have a beneficial effect on obesity, and it has even been suggested that these drugs contribute to obesity in certain cases [7,19,20]. In this scenario, there is a clear need for more effective pharmacological approaches that target the shared molecular pathways linking obesity and depression [21,22].

Evidence from family, twin, linkage, candidate-gene, and genome-wide association studies suggests that genetic factors account for a significant proportion of the overlap between depression and obesity [23–27]. Besides contributing substantially to the shared biological substrate of these disorders [28], multiple genetic variants influence the occurrence of specific symptoms, such as increases in appetite, during episodes of depression [29,30]. Moreover, polymorphisms in certain obesity-related genes may predict a poorer response to conventional antidepressants [31]. The genetic variants that have been tentatively flagged in this research are related not just to neurotransmission but also to diverse biological pathways, including those involved in cell division, apoptosis, glucose and lipid metabolism, energy utilisation, and immune–inflammatory regulation [32]. It is probable that a better understanding of the role played by these pathways, and the genes involved in their regulation, could lead to the development of safer and more effective treatments for both obesity and depression. A deeper understanding of the molecular genetics of this comorbidity could also lead to a more precise and personalised approach to the pharmacological management of obesity [33]. It was with this objective in mind that the current review was undertaken.

2. Review Process

The current study is a scoping review of studies examining the role of specific genetic variants in the relationship between depression and obesity. This review was carried out in accordance with the PRISMA extension guidelines for scoping reviews [34].

Study retrieval and search strategy: Studies were included if they evaluated the effect of specific genetic variants (either single or multiple polymorphisms) on depressive symptoms in obesity, on obesity in depressed individuals, or on the co-occurrence of depression and obesity. Studies that only provided general evidence of heritability, such as family and twin studies, were excluded, as were studies that evaluated polygenic risk scores (PRS) without specifying the relative contributions or the strengths of the associations with the specific variants that were included in the PRS.

The PubMed and EMBASE databases were searched using the following search terms: (“obesity” or “obese”) along with (“depression”, “depressive symptoms”, “depressive symptomatology”, or “major depression”), and (“genetic” (including variants), “gene”, “linkage”, “association”, “polymorphism” (including variants), or “genome-wide”). Epigenetic studies were not included in this review, as they have been extensively reviewed in a recent publication, which covered all published studies up to 2020 and identified variations in the methylation of three specific genes as being linked to both obesity and

depression [35]. However, the results of the current review are subsequently examined in the light of these epigenetic findings.

The PRISMA-ScR flow diagram for this study is provided below (Figure 1). Of a total of 1286 citations retrieved through the literature search, 261 duplicates were removed, and the remaining abstracts were screened for suitability for the current review. At this stage, 737 citations were excluded, as they were unrelated to the subject of this review. In the final step, the full texts of 288 papers were evaluated for inclusion in this review, based on the criteria mentioned in the first paragraph. A total of 260 papers were excluded at this stage, and a total of 28 publications were included in the final review. The reference lists of each included paper were searched for further relevant studies, but no additional papers were identified through this method.




Figure 1. PRISMA-ScR flow diagram for the current review.

Data charting and study quality assessment: All included studies were charted under the following headings: year of publication, study population and sample size, study methodology, study quality, and positive and negative study results. Study quality was assessed using the Q-Genie tool, which is a structured instrument to evaluate the quality of genetic studies. This tool evaluates the quality of a given genetic study across 11 distinct domains, covering the study rationale, definition of exposures and outcomes, selection of the study population, steps taken to minimise bias, statistical analysis and power, and appropriateness of the conclusions presented by the researcher. Based on the total score obtained, studies are classified as being of poor, moderate, or good quality [36]. It should be noted that the rating of a study as “poor” using Q-Genie does not disqualify it from inclusion in a review; however, any positive findings from such a study should be interpreted with caution due to the risk of false-positive results arising from various biases. As the single study rated “poor” in this review did not yield any positive results, it was included for the sake of completeness. This is in accordance with the PRISMA-ScR guidelines (item 16), which recommend a critical appraisal of such papers but not their exclusion [34].

Data synthesis: Following the extraction of the above data, information on the genetic variants identified, their known physiological roles, and the strength and consistency of the evidence supporting their links with depression and obesity were tabulated separately. Information on pharmacological agents related to each variant, either already marketed or in development, was retrieved where available, and the implications of this information were discussed from conceptual and clinical perspectives.

In addition to these conventional methods, an attempt to delineate protein–protein interactions and thereby identify potential molecular hubs that link obesity and depression was made through queries from the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. Two separate queries were conducted. The first included only those genes for which there were unequivocal positive findings ($n = 14$). The second included both the positive and equivocal findings from the current review, as well as the three genes identified as targets of epigenetic modification by the earlier review ($n = 19$).

A total of 28 studies was included in the final scoping review. Details of the studies included in this review are provided in Table 1.

Table 1. Genetic-association studies included in the current review.

Study and Year of Publication	Candidate Gene(s) and Polymorphisms Studied	Study Design	Study Population and Sample Size	Results	Study Quality (Q-Genie Quality Score)
Comings et al., 1991 [37]	<i>DRD2</i> (Taq1 SNP)	Single-gene association	Patients seeking psychiatric care, Caucasian (<i>n</i> = 314)	<i>DRD2</i> Taq1 A1 allele not significantly associated with depression or obesity	Poor (31)
Comings et al., 1996 [38]	<i>Ob</i> (D7S1875 repeat polymorphism)	Single-gene association	Young adults (age 26–30), Caucasian (<i>n</i> = 208)	<i>Ob</i> D7S1875 < 208 bp repeat polymorphism significantly associated with BMI and depressive symptoms, but only in women	Moderate (42)
Ejchel et al., 2005 [39]	<i>APOA4</i> (360 Gln/His SNP)	Single-gene association	Elderly adults (age ≥ 60) (<i>n</i> = 383)	<i>APOA4</i> 360 His allele associated with both obesity and depression	Moderate (39)
Chen et al., 2006 [40]	<i>APOA5</i> (−1131T→C SNP)	Single-gene association	Elderly adults (age 66–97) (<i>n</i> = 371)	<i>APOA5</i> -1131 C allele associated with obesity in the presence of depression	Moderate (37)
Krishnamurthy et al., 2008 [41]	<i>NR3C1</i> (Bcl1, N363S, rs33388 and rs33389 SNPs)	Single-gene association	Premenopausal women (age 21–45) with (<i>n</i> = 52) and without (<i>n</i> = 29) depression	<i>NR3C1</i> Bcl1 G/G genotype associated with greater abdominal obesity in women with depression; no significant association for other SNPs	Moderate (39)
Spalova et al., 2008 [42]	<i>NMB</i> (P73T SNP)	Single-gene association	Adults with (<i>n</i> = 292) and without (<i>n</i> = 155) obesity or overweight, Caucasian	No significant effect of <i>NMB</i> P73T on weight loss or depressive symptoms when followed up over 2.5 years after a weight-reduction programme	Moderate (42)
Fuemmeler et al., 2009 [43]	<i>MAOA</i> (30 bp VNTR) and <i>SLC6A4</i> (5-HTTLPR 44bp Ins/Del)	Multiple-gene association, gene x depression interaction	Adolescents (<i>n</i> = 1584)	<i>MAOA</i> high-activity variant associated with lower risk of obesity in the presence of depression in male but not female adolescents	Moderate (45)
Kivimaki et al., 2011 [44]	<i>FTO</i> (rs1421085 SNP)	Single-gene association	Adults (age 35–55) (<i>n</i> = 4145)	<i>FTO</i> rs1421085 C allele associated with depression and obesity in men, but not in women; link between risk allele and depression in men apparently independent of obesity	Good (48)
Rivera et al., 2012 [45]	<i>FTO</i> (10 SNPs)	Single-gene association; gene x depression interaction	Two independent samples of adults with (<i>n</i> = 3734) and without (<i>n</i> = 2499) major depression	Significant associations between 5 SNPs of <i>FTO</i> and BMI in adults with depression, but not in controls	Good (55)

Table 1. Cont.

Study and Year of Publication	Candidate Gene(s) and Polymorphisms Studied	Study Design	Study Population and Sample Size	Results	Study Quality (Q-Genie Quality Score)
Samaan et al., 2013 [46]	<i>FTO</i> (rs9939609 SNP)	Single-gene association	Pooled data from 4 samples of adults with ($n = 6561$) and without ($n = 21932$) depression	<i>FTO</i> rs993609 A variant associated with increased BMI but lower risk of depression	Good (53)
Beydoun et al., 2014 [47]	21 SNPs across 10 genes (<i>ABCG5</i> , <i>APOB</i> , <i>APOA4</i> , <i>APOE</i> , <i>BCMO1</i> , <i>CD36</i> , <i>LIPC</i> , <i>FABP2</i> , <i>LPL</i> , <i>SCARB1</i>) associated with serum-carotenoid levels	Multiple-gene association study	Adults (age 30–64), African-American ($n = 873$)	No specific association between any individual SNP and either obesity or depression	Good (49)
Harbron et al., 2014 [48]	<i>FTO</i> (rs1421085 and rs17817449 SNPs and haplotype)	Single-gene association; gene x depression interaction	Adults with obesity, Caucasian ($n = 133$)	<i>FTO</i> rs17817449 GG genotype associated with more severe depressive symptoms; rs1421085 C allele mediates relationship between depressive symptoms and BMI	Moderate (41)
Bielinski et al., 2015 [49]	<i>SLC6A4</i> (44-bp Ins/Del) and <i>HTR2A</i> (1438G/A SNP)	Multiple-gene association	Adults (age 18–73) with obesity, Caucasian ($n = 180$)	No significant association between either variant and depressive symptoms	Moderate (43)
Borkowska et al., 2015 [50]	<i>SLC6A4</i> (5-HTTLPR repeat polymorphism)	Single-gene association	Adults with obesity, Caucasian ($n = 390$)	5-HTTLPR L/L genotype associated with higher BMI and more severe depressive symptoms	Good (47)
Delacretaz et al., 2015 [51]	<i>MCHR2</i> (8 SNPs) and <i>MCHR2-AS1</i> (4 SNPs)	Multiple-gene association	Independent analyses of Caucasian adults with psychiatric disorders ($n = 816$) and in the general population ($n = 119,218$)	<i>MCHR2</i> rs7754794 TT genotype associated with lower BMI in patients with depression; similar but weaker association observed in the general population	Good (57)
McCaffery et al., 2015 [52]	8 SNPs at 6 loci previously associated with depressive symptoms	Multiple-gene association	Adults with obesity or overweight, multi-ethnic ($n = 2118$)	<i>KCNE1</i> rs1543654 associated with depressive symptoms; no significant associations for other SNPs	Good (46)
Samaan et al., 2015 [53]	21 SNPs previously associated with obesity	Multiple-gene association	Multi-ethnic adults with ($n = 3209$) and without ($n = 14,195$) depression	<i>TAL1</i> rs2984618 SNP significantly associated with both BMI and major depression	Good (53)
Yilmaz et al., 2015 [54]	<i>MC4R</i> (rs571312, rs17782313, rs489693, rs11872992 and rs8087522 SNPs)	Single-gene association	Adults (age 24–50), Caucasian ($n = 328$)	<i>MC4R</i> rs17782313 C allele associated with higher depressive symptoms and higher BMI, but the latter was not significant after correction	Good (51)

Table 1. Cont.

Study and Year of Publication	Candidate Gene(s) and Polymorphisms Studied	Study Design	Study Population and Sample Size	Results	Study Quality (Q-Genie Quality Score)
Quteineh et al., 2016 [55]	<i>CRTC1</i> (rs3746266 and rs6510997 SNPs)	Single-gene association	Pooled data from 3 samples of adults with ($n = 5344$) and without ($n = 5515$) major depression	No overall association between <i>CRTC1</i> polymorphisms and depression; <i>CRTC1</i> rs3746266 G allele and rs6510997 C allele associated with BMI in one of the samples	Moderate (43)
Bielinski et al., 2017 [56]	<i>COMT</i> (Val158Met) and <i>DAT1</i> (VNTR polymorphism)	Multiple-gene association	Adults (age 39–69) with obesity, Caucasian ($n = 364$)	<i>DAT1</i> 9-repeat allele associated with higher BMI and depressive symptoms; <i>COMT</i> Met/Met genotype associated with depressive symptoms	Moderate (42)
Hellgren et al., 2017 [57]	38 SNPs of four genes (<i>AKR1C2</i> , <i>AKR1C4</i> , <i>SRD5A1</i> and <i>SRD5A2</i>) involved in allopregnanolone synthesis	Multiple-gene association	Pregnant women, Caucasian ($n = 1351$)	<i>AKR1C2</i> rs28488494 SNP associated with BMI; <i>AKR1C2</i> rs1937863 SNP associated with postnatal depressive symptoms	Good (50)
Rivera et al., 2017 [58]	<i>FTO</i> (rs9939609 SNP)	Single-gene association; gene x depression interaction	Pooled data from 5 samples of adults with ($n = 6902$) and without ($n = 6799$) depression	<i>FTO</i> rs9939609 A variant associated with higher BMI in patients with depression but not in controls	Good (54)
Schepers and Markus, 2017 [59]	<i>SLC6A4</i> (5-HTTLPR repeat polymorphism)	Single-gene association	Healthy young adults (mean age 21.3) ($n = 827$)	5-HTTLPR S allele associated with higher BMI and depressive symptoms	Moderate (45)
Treutlein et al., 2017 [60]	<i>NPY2R</i> (rs6857715 SNP)	Single-gene association; gene x weight interaction	Adults with depression ($n = 595$) and general population controls ($n = 1295$)	<i>NPY2R</i> rs6857715 T allele associated with depression independent of increased weight; trend towards an association between T allele weight gain in depressed patients	Good (51)
Brummett et al., 2018 [61]	<i>HTR2C</i> (rs6318 SNP)	Single-gene association	Pooled data from 10 adult samples, Caucasian and African-American ($n = 27,161$)	No association between <i>HTR2C</i> rs6318 and either depressive symptoms or BMI	Good (54)
Hay et al., 2022 [62]	<i>PCSK9</i> and surrounding locus (7 lead SNPs identified through sequential analysis of biobank data)	Single-locus association	Data from adult Biobank samples, mixed ethnicity ($n = 73,627$)	<i>PCSK9</i> rs2647282 associated with BMI; no association between any <i>PCSK9</i> SNP and major depression	Good (49)

Table 1. Cont.

Study and Year of Publication	Candidate Gene(s) and Polymorphisms Studied	Study Design	Study Population and Sample Size	Results	Study Quality (Q-Genie Quality Score)
He et al., 2022 [63]	<i>HTR2C</i> (13 rare variants identified in a prior sample)	Single-gene association	Data from adult Biobank samples, Caucasian ($n = 153,352$)	<i>HTR2C</i> V61I variant associated with depression and obesity, but not significant after correction	Moderate (44)
Rahati et al., 2022 [64]	<i>MC4R</i> (rs17782313 SNP)	Single-gene association	Adults (age 20–50) with obesity or overweight, Iranian ($n = 403$)	<i>MC4R</i> rs17782313 C allele associated with higher depressive symptoms; CC genotype associated with higher body weight	Moderate (45)

Abbreviations: ABCG5, ATP-binding cassette sub-family G member 5 gene; AKR1C2, aldo-keto reductase family 1 member C2 gene; AKR1C4, aldo-keto reductase family 1 member C4 gene; APOA4, apolipoprotein A-IV gene; APOA5, apolipoprotein A-V gene; APOB, apolipoprotein B gene; APOE, apolipoprotein E gene; BCMO1, beta-carotene oxygenase 1 gene; BMI, body-mass index; CD36, cluster of differentiation 36 gene; COMT, catechol O-methyltransferase gene; CRTC1, CREB-regulated transcription coactivator 1 gene; DAT1, dopamine transporter gene; DRD2, dopamine type 2 receptor gene; FABP2, fatty-acid-binding protein 2 gene; FTO, fat-mass- and obesity-associated gene; HTR2A, serotonin type 2A receptor gene; HTR2C, serotonin type 2C receptor gene; LIPC, hepatic lipase gene; LPL, lipoprotein lipase gene; MAOA, monoamine oxidase A gene; MC4R, melanocortin 4 receptor gene; MCHR2, melanin-concentrating hormone receptor gene; NMB, neuromedin beta gene; NPY2R, neuropeptide Y type 2 receptor gene; NR3C1, glucocorticoid receptor gene; Ob, leptin gene; PCSK9, proprotein convertase subtilisin/kexin type 9 gene; SCARB1, scavenger receptor class B1 gene; SLC6A4, serotonin transporter gene; SNP, single-nucleotide polymorphism; SRD5A1, 3-oxo-5 α -steroid 4-dehydrogenase 1 gene; SRD5A2, 3-oxo-5 α -steroid 4-dehydrogenase 2 gene; TAL1, T-cell acute lymphocytic leukemia protein 1 gene.

3. Methodological Characteristics and Quality of the Included Studies

Of the 28 studies included in this review, the majority ($n = 20$) were association studies involving a single gene or locus; only eight studies examined multiple genes across distinct loci. Five of the 28 included studies examined interaction effects between genotype and either depression or obesity. Nine studies used a case-control design: eight compared individuals with depression to healthy controls, and one compared individuals with obesity to controls. The remaining 19 studies did not have a control or comparator group.

Study populations in the uncontrolled studies were as follows: adults in the general population ($n = 6$), adults with obesity ($n = 6$), elderly adults ($n = 2$), young adults ($n = 2$), adolescents ($n = 1$), pregnant women ($n = 1$), and adult patients seeking psychiatric care ($n = 1$). Ethnicity was specified in 17 of the 28 studies as being Caucasian ($n = 12$), African-American ($n = 2$), or multi-ethnic ($n = 3$); in the remaining 11 studies, ethnicity was not specifically mentioned.

The mean Q-Genie score for the included studies was 46.3 ± 6.1 , indicating good study quality. Fourteen studies were rated “good”, 13 were rated “moderate”, and only one study received a rating of “poor.” The average Q-Genie score for sources of possible bias was 4.1, indicating a low risk of bias, whereas the average score for study power was 4.2, indicating generally adequate study power. Concerns related to individual studies being underpowered were identified in eight of the 28 (28.6%) included studies.

4. Genetic Associations Identified through the Review

The 28 studies included in this review evaluated the effects of variants in 54 distinct genes on the relationship between obesity and depression. Among these variants, replicated positive associations were identified for two genetic loci, positive associations in single studies were identified for 12 genetic loci, and mixed or equivocal associations (i.e., both positive and negative findings) were reported for a further two loci. Details of these candidate genes and their physiological significance are summarised in Table 2.

Table 2. Functional significance and quality of evidence for genes associated with both obesity and depression.

Genetic Locus	Physiological Effects of Gene Product	Impact on Obesity and Depression
Genes with replicated associations		
<i>FTO</i> (5 studies)	DNA/RNA demethylase enzyme that influences food intake, adiposity, and energy expenditure	Multiple SNPs associated with elevated BMI in depression but not in general samples [45] rs9939609 A allele associated with higher BMI both in general samples and in patients with depression; also associated with lower depressive symptoms in general samples [46,58] rs17817749 GG genotype associated with elevated depressive symptoms in adults with obesity [48] rs1421085 C allele interacts with depressive symptoms to influence higher BMI [44]
<i>MC4R</i> (2 studies)	G-protein-coupled, membrane-bound receptor for α -melanocyte-stimulating hormone	rs17782313 C allele associated with increased depressive symptoms in adults both with and without obesity [54] CC genotype associated with increased body weight in adults with obesity [64]
Genes with positive findings in single studies		
<i>AKR1C2</i>	Reduction of 5α -dihydroprogesterone to allopregnanolone; one of two isoforms expressed in the brain	rs28488494 associated with BMI and rs1937863 associated with post-partum depressive symptoms in pregnant women [57]
<i>APOA5</i>	Component of high-density lipoprotein (HDL); involved in regulation of plasma-triglyceride levels	−1131 C allele associated with obesity in elderly adults with depression [40]

Table 2. Cont.

Genetic Locus	Physiological Effects of Gene Product	Impact on Obesity and Depression
<i>COMT</i>	O-methylation and inactivation of catecholamine neurotransmitters—dopamine, epinephrine, norepinephrine	rs4680 Met/Met genotype associated with depressive symptoms in adults with obesity [56]
<i>DAT1</i>	Reuptake of dopamine into presynaptic neurons	9-repeat allele associated with higher BMI and elevated depressive symptoms [56]
<i>KCNE1</i>	Regulation of voltage-gated potassium channel activity in cardiac muscle, inner ear, and brain	rs1543654 associated with depressive symptoms in adults with obesity [52]
<i>MAOA</i>	Catabolism of monoamine neurotransmitters—dopamine, serotonin, norepinephrine	High-activity variant associated with reduced obesity in adolescent girls with depression [43]
<i>MCHR2</i>	G-protein-coupled, membrane-bound receptor for melanin-concentrating hormone	rs7754794 TT genotype associated with lower BMI in patients with depression [51]
<i>NPY2R</i>	Receptor for neuropeptide Y, which is involved in the stress response, eating behaviour, cognition, and pain perception	rs6857715 T allele associated with depression independent of BMI [60] Trend towards an association between this allele and increased BMI in patients with depression [60]
<i>NR3C1</i>	Nuclear receptor for cortisol and other glucocorticoid hormones; involved in regulation of carbohydrate metabolism, immune-inflammatory activity, and the stress response	Bcl1 G/G genotype associated with greater obesity in women with depression [41]
<i>Ob</i> (Leptin)	Centrally active hormone secreted by adipose cells; regulates satiety and energy expenditure	D7S1875 < 208 bp variant associated with depressive symptoms and higher BMI in women [38]
<i>PCSK9</i>	Proprotein convertase enzyme; regulates serum cholesterol levels by modulating the number of low-density lipoprotein receptors (LDL)	rs2647282 associated with BMI in adults; no association with depression [62]
<i>TAL1</i>	Transcription factor involved in differentiation of erythroid and myeloid cells	rs2984618 associated with higher BMI and risk of major depression in adults [53]
Genes with mixed positive and negative findings		
<i>SLC6A4</i> ^a	Reuptake of serotonin into presynaptic neurons	5-HTTLPR s allele associated with higher BMI and depressive symptoms in young adults [59] 5-HTTLPR l/l genotype associated with higher BMI and more severe depressive symptoms in adults with obesity [50]
<i>APOA4</i> ^b	Component of very-low-density lipoprotein (VLDL) and chylomicrons; activator of enzymes involved in lipid metabolism; involved in regulation of serum cholesterol levels	360 Gln/His associated with obesity and depression in elderly adults [39]

^a Two positive and two negative studies. ^b One positive and one negative study.

4.1. Replicated Candidate-Gene Associations

Replicated findings across two or more independent populations were identified for the fat-mass- and obesity-related gene (FTO) and the melanocortin 4 receptor gene (MC4R). FTO, located on chromosome 16q, encodes a nucleic-acid demethylase enzyme that regulates the expression of multiple genes through its regulation of DNA and RNA methylation, exerting complex effects on glucose and lipid metabolism as well as food intake and satiety [65,66]. The effects of variants of this gene on the links between obesity and depression are complex: it has been associated both with elevated depressive symptoms in obese adults and with an increased body-mass index (BMI) in depressed individuals. There is also evidence of an interaction between a specific SNP of this gene and the presence of depressive symptoms in influencing BMI. Thus, FTO variants appear to exert bidirectional effects on the link between depression and obesity.

The MC4R gene encodes a receptor for α -melanocyte-stimulating hormone (melanocortin) that influences both food intake and energy expenditure; the action of melanocortin at MC4R is influenced by several factors, including neurotransmitters such as serotonin, other hormones such as leptin, and circulating levels of fatty acids [67]. Only a single functional polymorphism (rs17782313) of this gene has been studied in relation to obesity and depression; in one study, the C allele of this SNP was associated with elevated depressive symptoms independent of weight, whereas in the other, homozygosity for this allele was associated with higher weight in adults with obesity. Unlike variants in FTO, MC4R rs17782313 appears to have independent effects on depression and obesity.

4.2. Candidate-Gene Associations from Single Studies

Of the remaining genes identified in this review, three (COMT, DAT1, and MAOA) are involved in monoaminergic neurotransmission and have been extensively studied in relation to the monoamine hypothesis of depression. COMT and DAT1 variants were both associated with elevated depressive symptoms in adults with obesity, but only the latter was associated with elevated BMI. The significance of findings related to MAOA are unclear; the higher-activity variant of this gene was associated with lower depressive symptoms in obese adolescents, but this effect appeared to be gender specific, and there are no studies of MAOA in relation to depression and obesity in adults.

Apart from monoamine transmitters, a single study implicated a functional variant of the NPY2 gene in both depressive symptoms and increased BMI. NPY2 encodes a receptor for neuropeptide Y, a peptide neurotransmitter that influences a wide range of behavioural and physiological processes, including food intake, the stress response, and mood [68].

Four studies implicated genes that encode specific hormones or their receptors. Among these, AKR1C2, involved in the synthesis of allopregnanolone, was associated with increased body-mass index and post-partum depressive symptoms in pregnant women, though different SNPs were involved in each association. MCHR2 encodes a receptor for melanin-concentrating hormone (MCH). In certain animal species, MCH's primary function is to regulate melanin concentrations and colour changes; however, it also plays a key role in regulating arousal and energy balance in mammals [69]. Homozygosity for a specific allele of the rs7754794 SNP of this gene appeared to exert a protective effect against obesity in individuals with depression. NR3C1 encodes the receptor for glucocorticoid hormones such as cortisol, thereby playing a central role in both stress responsiveness and energy balance. Functional variants in this gene have been consistently associated with depression [70]. In the current review, homozygosity for a specific variant of NR3C1 (Bcl1 G/G) was linked to elevated obesity in women with depression. Finally, the Ob gene encodes the hormone leptin, which plays a central role in regulating both food intake and energy metabolism [71]. A specific repeat polymorphism of Ob was associated with both obesity and depression, but only in women.

The remaining genes identified in this review represent diverse physiological and biochemical processes. These include proteins involved in the regulation of lipid levels (APOA5, PCSK9) which appear to be associated with obesity but not with depressive symptoms, a regulator of voltage-gated potassium channels (KCNE1) and a transcription factor (TAL1) best known as a regulator of haematopoiesis. The latter two associations are particularly intriguing, as they were previously implicated in other forms of disease but not specifically in obesity or depression.

4.3. Identification of Interactions between the Products of Identified Genes

To extend the results of this review beyond the scope of single-gene associations, an attempt was made to examine interactions between the proteins encoded by these genes. To this end, the genes identified in this review were entered into the STRING database and a map of possible protein–protein interactions was constructed, which is illustrated in Figure 2. This process was carried out in two steps. In the first, only the 14 genes with unequivocal evidence of an association with depression and obesity, as noted in Table 2,

were entered. In this model (marked in Figure 2a), associations could be identified between 10 of the 14 protein products. Genes related to brain monoaminergic transmission (*COMT*, *SLC6A3*, and *MAOA*) were strongly linked to the glucocorticoid receptor *NR3C1*, which was itself linked to *LEP* (*Ob*). *LEP* was, in turn, linked with *FTO* and *MC4R*. *FTO* was linked to genes related to lipid metabolism (*APOA5* and *PCSK9*), whereas *MC4R* showed a significant connection to *NPY2R*. Thus, there appear to be two distinct “networks”—one more directly associated with stress and depression, and one with energy utilisation and lipid metabolism—which appear to be linked via the stress-related genes *NR3C1* and *LEP*.




Figure 2. Maps of possible protein–protein interactions for the genes identified in the current review, based on the STRING database.

In the second model, all the 16 genes identified as having some supporting evidence in Table 2, as well as the three genes identified in the earlier review of the epigenetics of obesity and depression (*BDNF*, *SORBS2*, and *TAPBP*) [35], were entered into the database. The resulting map (marked in Figure 2b) demonstrates protein–protein interactions of likely significance between 13 of the 19 genes included. Once again, there appeared to be a “network” involving genes related to monoaminergic transmission, neural plasticity, and the stress response, which was in turn linked to another “network” related to food intake, energy utilisation, and lipid metabolism through the genes *LEP*, *MC4R*, and *FTO*. The possible significance of these findings is discussed below.

5. Discussion

The current review identified 14 candidate genes that appear to be involved in the link between obesity and depression, of which two were replicated in independent populations. Evidence from studies of large general-population samples suggests that most cases of obesity are not caused by alterations in single genes but by the additive or interactive effects of several genes involved in distinct physiological pathways. Moreover, this polygenic architecture appears to overlap significantly with that of depression [25–28,72–76]. Existing treatments for obesity are effective in some patients, but their use is often limited by adverse effects, and it is not known whether they are effective in the presence of comorbid depression [77]. Moreover, there is no evidence that antidepressant drugs are themselves useful in treating obesity, and some of them may be associated with significant weight gain [78]. Against this background, the current review was undertaken to identify novel molecular targets that could lead to more effective and well-tolerated treatments for these

comorbid conditions. Potential pharmacological approaches that target these pathways, both synthetic and natural, are summarised in Table 3 below. Drugs acting via standard targets for antidepressant medications are not covered here, as their use in obesity has been extensively reviewed elsewhere [19].

Table 3. Potential pharmacological therapies for comorbid obesity and depression, based on genetic studies.

Target Gene	Synthetic Agents	Natural Agents
<i>FTO</i>	Selective inhibitors of FTO demethylase ^a	<i>Angelica sinensis</i> ext. Rhein
<i>MC4R</i>	Bremelanotide ^b Setmelanotide ^b	<i>Moringa oleifera</i> ext. Daisaikoto
<i>AKR1C2</i>	Selective AKR1C2 inhibitors ^a	Astaxanthin Bai He Gun Jin Tiang
<i>KCNE1</i>	-	<i>Coriandrum sativum</i> ext. Gintoin Rottlerin
<i>MCHR2</i>	GW803430 ^a	-
<i>NPY2R</i>	Neuropeptide Y, intranasal ^a Combined NPY2R and GLP-1 agonists ^a	<i>Panax ginseng</i> ext.
<i>NR3C1</i>	CORT125281 ^a PT150 ^c	<i>Aesculus turbinata</i> ext. Curcumin Baihe Zhimu Xingpi Jieyu
<i>Ob</i>	-	<i>Commiphora myrrha</i> ext. <i>Nelumbo nucifera</i> ext. <i>Prunus persica</i> ext.
<i>PCSK9</i>	Alirocumab ^b Evolocumab ^b	<i>Lysimacha vulgaris</i> ext. <i>Protium heptaphyllum</i> ext. <i>Salvia plebeia</i> ext.
<i>TAL1</i>	PIK-75 ^a	-

Abbreviations: *AKR1C2*, aldo-keto reductase family 1 member C2 gene; Ext., extract; *FTO*, fat-mass- and obesity-associated gene; GLP-1, glucagon-like peptide 1; *MC4R*, melanocortin receptor type 4 gene; *MCHR2*, melanin-concentrating hormone type 2 receptor gene; *NPY2R*, neuropeptide Y type 2 receptor gene; *NR3C1*, glucocorticoid receptor gene; *Ob*, leptin gene; *PCSK9*, proprotein convertase subtilisin/kexin type 9 gene; *TAL1*, T-cell acute lymphocytic leukaemia protein 1 gene. ^a Under development or for experimental use in animal models only. ^b Randomised controlled trials and/or available on the market for use in human patients. ^c Preclinical trials ongoing in humans.

5.1. Synthetic Pharmacological Therapies

Given the preponderance of research implicating functional variants of *FTO* in the association between obesity and depression, it is natural to consider whether pharmacological manipulation of the *FTO* gene product—namely, the demethylase enzyme encoded by this gene—might be effective in treating these conditions. Though there are no currently available pharmacological agents for this purpose, there are ongoing efforts to develop small-molecule FTO inhibitors for the treatment of other disorders in humans, particularly certain types of cancer [79]. This research is still in its early stages, but there is evidence that it is possible—at least in principle—to develop selective inhibitors of FTO that do not exert comparable effects on other demethylase enzymes, and that these compounds are active in in vitro models related to cancer-cell lines [80]. Such compounds, if demonstrated to be safe and effective in humans, may represent a valuable and innovative treatment approach to the treatment of comorbid obesity and depression.

Evidence of an association between variants in *MC4R* and the presence of obesity and depression was identified in two independent populations. Two selective agonists of this receptor, bremelanotide and setmelanotide, have been developed and assessed for safety

and efficacy in humans. There is evidence that bremelanotide is associated with modest benefits in terms of weight reduction and reduced caloric intake in a proof-of-concept trial involving women with obesity. However, this drug has to be administered parenterally and was associated with high rates of injection-site reactions [81]. Setmelanotide has been evaluated in randomised controlled trials in both children and adults, but only in patients with monogenic obesity due to isolated loss-of-function mutations, such as Bardet–Biedl syndrome [82,83]. This drug also requires parenteral administration and is associated with high rates of both injection-site effects and other adverse events such as increased skin pigmentation, nausea, and diarrhoea. There is evidence from animal models that antagonists (rather than agonists) of MC4R can ameliorate depressive-like symptoms; thus, it is not clear which degree of activation of this receptor would be optimal in managing patients with both obesity and depression [84,85]. Non-peptide modulators of MC4R are also under development and may offer advantages in terms of pharmacokinetics and adverse effects [86].

Studies of melanin-concentrating hormone modulators in laboratory settings are complicated by the facts that rodents, which are the most frequently used animals in these studies, do not express the MCHR2 receptor. However, administration of an experimental MCHR1 antagonist, GW803430, was associated with reductions in both obesity and depression in a rat model [87]. Selective antagonists of MCHR2 have been developed for use in other mammals, such as dogs and monkeys [88]. These agents are not currently available for experimental or clinical use in humans but represent a potentially valuable line of research in the management of comorbid obesity and depression.

In an animal model, administration of neuropeptide Y was found to synergise with pharmacological manipulation of MC4R to alleviate depressive-like behaviours induced by stress. Experimental agonists of the Y2 receptor exist for use in research and have been considered for use as novel antidepressants, but none have been developed for use in humans [89]. It has recently been suggested that combined agonism of the Y2 receptor and the glucagon-like peptide-1 (GLP-1) receptor may be a useful approach to treating addictive behaviours in humans [90]. GLP-1 agonists have shown independent evidence of efficacy in treating obesity in randomised controlled trials [91]. It is therefore plausible that such drugs could be useful in treating comorbid obesity and depression, particularly when associated with increased food intake or compulsive eating.

The NR3C1 receptor has far-reaching physiological effects that extend beyond its associations with depression and obesity. Therefore, direct pharmacological manipulation of this receptor carries definite risks [92]. Nevertheless, a competitive NR3C1 antagonist, named PT150, has been developed for use in humans and appears to be well tolerated in phase I trials [93]. In a mouse model of obesity, another novel NR3C1 antagonist, CORT125281, was associated with weight reduction and an improved lipid profile [94]. Given the existing evidence for the benefits of glucocorticoid receptor antagonism in patients with resistant depression [95], it is possible that drugs such as PT150 may be useful in a subset of patients with depression and obesity resistant to standard treatments.

PCSK9 inhibitors are already in use as lipid-lowering agents in clinical practice and are effective for this indication when added to standard therapies [96]. These drugs have not been evaluated for specific effects on obesity and depression in humans. A study of mice genetically engineered to carry a PCSK9 inhibitor showed that these animals maintained a normal body mass even when given a high-fat diet [97]. However, PCSK9 inhibitors have been associated with a slight but significant and paradoxical increase in depressive symptoms in humans [98]; therefore, caution is required when evaluating these drugs in patients with both disorders.

Among the other molecular targets identified in this review, synthetic inhibitors of *AKR1C2* and *TAL1* have been investigated as treatment approaches in cancer chemotherapy; however, they are not yet available for use in human subjects, and it is not clear what role they might play in the management of obesity associated with depression [99,100].

5.2. Natural Compounds

Certain natural compounds have been identified as potentially acting through the molecular pathways identified in this review. Though the evidence for their use in comorbid obesity and depression is largely in the preclinical stage, it is possible that some of these compounds may represent safe and effective treatment approaches to these conditions or may serve as pharmacological “leads” to such treatments.

Two plant products have been identified as having potentially beneficial effects through their actions on *FTO*. Extracts from the roots of *Angelica sinensis*, which is used in traditional Chinese medicine, have been shown to suppress weight gain in rodent models, and this suppression was associated with increased expression of *FTO*, as well as with increased methylation of the *FTO*-promoter region. However, this plant extract is a complex mixture of several compounds, and it is not known which of these molecules is responsible for this specific effect [101]. Rhein, an anthraquinone molecule extracted from *Rheum L.* rhizomes used in traditional medicine, has been shown to inhibit the enzymatic action of *FTO* and was observed to inhibit adipocyte differentiation in vitro [102].

Similarly, there is evidence that two phytochemicals may have anti-obesity effects through their actions on *MC4R* expression. Extracts from the leaves of *Moringa oleifera*, a plant used both for food and in traditional medicine, reduced weight gain and adiposity in rats fed a high-fat diet. These effects were associated with increased *MC4R* expression [103]. Daisaikoto, a traditional Kampo (Japanese) medicine, reduced both body weight and fatty liver in mice in whom *MC4R* was knocked out and who were fed a high-fat diet [104].

Regarding the other candidate genes identified in this review, there is preliminary evidence that phytochemicals acting on *NR3C1* may be effective both in obesity and in depression. Escin, a saponin compound extracted from *Aesculus turbinata*, has anti-obesity effects in mice, which were partly mediated through its effects on this pathway [105]. Two Chinese herbal preparations have been identified as acting on *NR3C1* and possessing potential antidepressant properties based on in silico network analyses [106,107], as does curcumin, extracted from turmeric [108]. Bioactive compounds derived from Korean ginseng (*Panax ginseng*) have been found to reduce obesity in rodent models, and this effect appears to be associated with a reduction in neuropeptide Y levels; however, it is not known to what extent these correlate with altered activity at the Y2 receptor [109]. Several plant compounds have been shown to reduce elevated leptin levels in rodent models of obesity, and these effects correlate with their ability to prevent or attenuate obesity in these models [110–112]. The carotenoid compound asthaxanthin [113] and the Chinese herbal preparation Bai He Gu Jin Tian, which contains 10 distinct herbs [114], have both been identified as acting on *AKR1C2* in silico, which may be associated with anti-depressant and anti-obesity effects. Phytochemicals derived from *Lysimachia vulgaris*, *Protium heptaphyllum*, and *Salvia plebeia* have been shown to reduce *PCSK9* expression in vitro, though these have been investigated as lipid-lowering agents and not specifically for obesity or depression [115–117]. Finally, certain plant products have been shown to be pharmacologically active at the *KCNE1* binding site; however, these properties have been evaluated in the context of anti-arrhythmic or anti-convulsant activities [118–120].

5.3. Mapping Protein–Protein Interactions and Possible Molecular Hubs

When examining possible networks of interactions between the protein products of genes implicated in obesity and depression (Figure 2), similar findings were obtained both when considering the genes identified in this review and when incorporating those identified as being subject to epigenetic modification in obesity and depression. In both cases, there appeared to be two closely linked “networks”—one involving genes related to monoaminergic transmission and neural plasticity and one related to energy intake and utilisation. In both cases, the “bridge” between these two tightly interconnected networks appeared to involve the genes *NR3C1*, *Ob* (*LEP*), *FTO*, and *MC4R*. These findings suggest that therapies for co-occurring depression and obesity may be more effective if they are directed at one or more of these molecular targets. They also suggest that evaluation of

the efficacy of anti-obesity treatments, particularly in the presence of depression, may be improved by the study of these genes or their products as potential biomarkers: this could include measures of the methylation of these genes, or the expression of their respective protein products, in relation to changes in body weight or in depressive symptoms. These findings might also explain the relative inefficacy of antidepressants in the management of obesity, as their effects may be confined to the first network without meaningfully influencing the second.

It should also be noted that for six of the genes included in this analysis—AKR1C2, KCNE1, MCHR2, SORBS2, TAL1, and TAPBP—no significant protein–protein interaction was identified. This may reflect limitations in the methodology employed (for example, AKR1C2 was identified in a study of pregnant women and may not be related to obesity in other populations) or in our existing knowledge of protein–protein networks. It remains possible that examination of the physiological effects of these genes in the context of depression and obesity could yield valuable insights into the pathophysiology and treatment of these conditions. One likely mechanism of importance in this context is immune–inflammatory dysregulation, which is known to occur in both depression and obesity and in which some of these genes have already been implicated [35].

5.4. Implications for Clinical Practice and Research

Depression and obesity, besides being highly comorbid with one another, share the property of being complex conditions, resulting from the interaction of multiple vulnerability genes with environmental factors such as childhood adversity, diet, physical activity, and stress [121,122]. Due to their complex nature, it is unlikely that a single class of treatments would be effective for all patients suffering from these disorders. This has led to interest in a personalised-medicine approach to both depression and obesity [123,124]. One way of achieving this is through the use of polygenic-risk scores, but these have not been specifically evaluated in the prediction of treatment outcomes in obesity and depression and are crucially dependent on the availability of genetic data from diverse populations [125]. In the absence of such wide-ranging data, it is possible that pre-treatment screening for the functional polymorphisms identified in this review, particularly those related to the *FTO* and *MC4R* genes, may help in predicting treatment outcomes of both conventional and novel treatments for these conditions [126]. Alternately, peripheral assays of the levels of particular enzymes or hormones, or measures of receptor expression, may correlate with the response to specific treatments for depression and obesity: such an effect has already been demonstrated to some extent for the anti-obesity medication sibutramine, which causes a significant reduction in serum-leptin levels post-treatment [127].

Prior to the initiation of formal drug-development processes, it is important that the evidence identified in this review be replicated in diverse populations. Attempts should also be made to elucidate the cellular and tissue-level mechanisms through which these gene products are associated with obesity or depression. Such research would not only place future drug development on a firmer footing but also lead to the elucidation of further novel molecular targets, as well as interactions between those identified in current research [128–131]. Based on these results, both existing natural and synthetic compounds, as well as “leads” derived from such compounds, could be tested in animal models of obesity with associated depressive-like behaviours or symptoms [132,133]. When evaluating such compounds in clinical trials, an emphasis must be placed on rigorous standards for drug safety as well as efficacy, given the concerning history of serious adverse drug reactions associated with prior treatments marketed for both disorders [134,135]. In addition, attempts should be made to correlate any observed benefits achieved through the use of these drugs with changes in objective biomarkers, such as alterations in the expression of target genes, inhibition of target enzymes, or changes in the circulating levels of specific hormones.

6. Limitations

The current review is subject to certain limitations. First, it is based on the available literature on association studies in obesity and depression obtained through a search of selected databases and could not account for unpublished or “grey” literature. Second, though the included studies were of an acceptable quality overall, several of them were subject to important limitations regarding phenotype definition, selection of candidate genes, and study power. Third, most published studies were conducted in high-income countries in which the majority of the population is of Caucasian ethnicity; hence, it is not clear to what extent these results can be generalised to other countries or ethnic groups. Fourth, some of the included studies were conducted in special populations, such as pregnant women, adolescents, and the elderly, in whom the biological processes related to obesity and depression may be unique to some extent. Therefore, these findings may not be directly applicable to obesity or depression in the general population. Fifth, caution is required when extrapolating from the results of animal or in vitro studies to human subjects, and most of the molecules mentioned in Table 3 are not currently available for clinical use. Sixth, certain natural compounds that exhibit in vitro or in silico evidence of efficacy may have pharmacokinetic properties that limit their use in human subjects; in such cases, phytochemicals should be considered “lead molecules” rather than treatments in themselves [136]. Finally, it is possible that epigenetic modifications of gene expression, rather than polymorphisms of candidate genes themselves, may be more directly related to the pathogenesis of obesity and depression at a cellular level [34]; therefore, it is important not to place undue weight on association studies alone.

7. Conclusions

Despite certain limitations, the current review identified certain novel molecular targets for the pharmacological management of obesity with comorbid depression or depressive symptoms. These targets included not only the well-known fat-mass- and obesity-associated protein gene *FTO* but also hormone receptors such as *MC4R*, *MCHR2*, and *NR3C1*; neurotransmitter receptors such as *NPY2R*; and genes not previously associated with these conditions, such as *KCNE1*, *PCSK9*, and *TAL1*. Available evidence suggests that certain natural and synthetic compounds targeting these molecular pathways may represent advances in the management of both disorders, though much of this evidence is at a preliminary stage and requires replication and verification in animal and human models. It is hoped that the findings of this review will be of use to those involved in the development and testing of novel drug therapies for obesity and depression, as well as to those advocating a personalised-medicine approach towards these disorders.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No original research data were generated for the purpose of this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. World Obesity Federation. Prevalence of Obesity. Available online: <https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity> (accessed on 21 January 2023).
2. Wong, M.C.S.; Huang, J.; Wang, J.; Chan, P.S.F.; Lok, V.; Chen, X.; Leung, C.; Wang, H.H.X.; Lao, X.Q.; Zheng, Z.-J. Global, regional, and time-trend prevalence of central obesity: A systematic review and meta-analysis of 13.2 million subjects. *Eur. J. Epidemiol.* **2020**, *35*, 673–683. [CrossRef]
3. Franks, P.W.; Atabaki-Pasdar, N. Causal inference in obesity research. *J. Intern. Med.* **2017**, *281*, 222–232. [CrossRef]
4. Luppino, F.S.; de Wit, L.M.; Bouvy, P.F.; Stijnen, T.; Cuijpers, P.; Penninx, B.W.J.H.; Zitman, F.G. Overweight, obesity and depression: A systematic review and meta-analysis of longitudinal studies. *Arch. Gen. Psychiatry* **2010**, *67*, 220–229. [CrossRef]

5. Sutaria, S.; Devakumar, D.; Yasuda, S.S.; Das, S.; Saxena, S. Is obesity associated with depression in children? Systematic review and meta-analysis. *Arch. Dis. Child.* **2019**, *104*, 64–74. [[CrossRef](#)]
6. Marx, P.; Antal, P.; Bolgar, B.; Bagdy, G.; Deakin, B.; Juhasz, G. Comorbidities in the diseasome are more apparent than real: What Bayesian filtering reveals about the comorbidities of depression. *PLoS Comput. Biol.* **2017**, *13*, e1005487. [[CrossRef](#)]
7. Wurtman, J.J.; Wurtman, R.J. Depression can beget obesity can beget depression. *J. Clin. Psychiatry* **2015**, *76*, e1619–e1621. [[CrossRef](#)]
8. Jokela, M.; Hamer, M.; Singh-Manoux, A.; Batty, D.; Kivimaki, M. Association of metabolically healthy obesity with depressive symptoms: Pooled analysis of eight studies. *Mol. Psychiatry* **2014**, *19*, 910–914. [[CrossRef](#)]
9. Konttinen, H. Emotional eating and obesity in adults: The role of depression, sleep and genes. *Proc. Nutr. Soc.* **2020**, *79*, 283–289. [[CrossRef](#)]
10. Schachter, J.; Martel, J.; Lin, C.-S.; Chang, C.-J.; Wu, T.-R.; Lu, C.-C.; Ko, Y.-F.; Lai, H.-C.; Ojcius, D.M.; Young, J.D. Effects of obesity on depression: A role for inflammation and the gut microbiota. *Brain Behav. Immun.* **2018**, *69*, 1–8. [[CrossRef](#)]
11. Ouaknin, S.R.S.; Barreira, D.P.; Gois, C.J. Depression and obesity: Integrating the role of stress, neuroendocrine dysfunction and inflammatory pathways. *Front. Endocrinol.* **2018**, *9*, 431. [[CrossRef](#)]
12. Milano, W.; Ambrosio, P.; Carizzzone, F.; De Biasio, V.; Di Munzio, W.; Foia, M.G.; Capasso, A. Depression and obesity: Analysis of common biomarkers. *Diseases* **2020**, *8*, 23. [[CrossRef](#)]
13. Opel, N.; Thalamuthu, A.; Milaneschi, Y.; Grotegerd, D.; Flint, C.; Leenings, R.; Goltermann, J.; Richter, M.; Hahn, T.; Woditsch, G.; et al. Brain structural abnormalities in obesity: Relation to age, genetic risk, and common psychiatric disorders: Evidence through univariate and multivariate mega-analysis including 6420 participants from the ENIGMA MDD working group. *Mol. Psychiatry* **2021**, *26*, 4839–4852. [[CrossRef](#)] [[PubMed](#)]
14. Cao, B.; Xu, J.; Li, R.; Teopiz, K.M.; McIntyre, R.S.; Chen, H. Interventions targeting comorbid depression and overweight/obesity: A systematic review. *J. Affect. Disord.* **2022**, *314*, 222–232. [[CrossRef](#)]
15. Woo, Y.S.; Seo, H.-J.; McIntyre, R.S.; Bahk, W.-M. Obesity and its potential effects on antidepressant treatment outcomes in patients with depressive disorders: A literature review. *Int. J. Mol. Sci.* **2016**, *17*, 80. [[CrossRef](#)]
16. Grigolon, R.B.; Trevisol, A.P.; Gerchman, F.; Bambokian, A.D.; Magee, T.; McIntyre, R.S.; Gomes, F.A.; Brietzke, E.; Mansur, R.B. Is obesity a determinant of success with pharmacological treatment for depression? A systematic review, meta-analysis and meta-regression. *J. Affect. Disord.* **2021**, *287*, 54–68. [[CrossRef](#)] [[PubMed](#)]
17. Fabricatore, A.N.; Wadden, T.A.; Higginbotham, A.J.; Faulconbridge, L.F.; Nguyen, A.M.; Heymsfield, S.B.; Faith, M.S. Intentional weight loss and changes in symptoms of depression: A systematic review and meta-analysis. *Int. J. Obes.* **2011**, *35*, 1363–1376. [[CrossRef](#)] [[PubMed](#)]
18. Fabricatore, A.N.; Wadden, T.A.; Moore, R.H.; Butryn, M.L.; Heymsfield, S.B.; Nguyen, A.M. Predictors of attrition and weight loss success: Results from a randomized controlled trial. *Behav. Res. Ther.* **2009**, *47*, 685–691. [[CrossRef](#)]
19. Rodriguez, J.E.; Campbell, K.M. Past, present, and future of pharmacologic therapy in obesity. *Prim. Care* **2016**, *43*, 61–67. [[CrossRef](#)]
20. Lee, S.H.; Paz-Filho, G.; Mastronardi, C.; Licinio, J.; Wong, M.-L. Is increased antidepressant exposure a contributory factor to the obesity pandemic? *Transl. Psychiatry* **2016**, *15*, e759. [[CrossRef](#)]
21. Caron, A.; Michael, N.J. New horizons: Is obesity a disorder of neurotransmission? *J. Clin. Endocrinol. Metab.* **2021**, *106*, e4872–e4886. [[CrossRef](#)]
22. Kornhuber, J.; Gulbins, E. New molecular targets for antidepressant drugs. *Pharmaceuticals* **2021**, *14*, 894. [[CrossRef](#)]
23. Afari, N.; Noonan, C.; Goldberg, J.; Roy-Byrne, P.; Schur, E.; Golnari, G.; Buchwald, D. Depression and obesity: Do shared genes explain the relationship? *Depress. Anxiety* **2010**, *27*, 799–806. [[CrossRef](#)] [[PubMed](#)]
24. Jokela, M.; Berg, V.; Silventoinen, K.; Batty, G.D.; Singh-Manoux, A.; Kaprio, J.; Smith, G.D.; Kivimaki, M. Body mass index and depressive symptoms: Testing for adverse and protective associations in two twin cohort studies. *Twin Res. Hum. Genet.* **2016**, *19*, 306–311. [[CrossRef](#)] [[PubMed](#)]
25. Wang, R.; Snieder, H.; Hartman, C.A. Familial co-aggregation and shared heritability between depression, anxiety, obesity and substance use. *Transl. Psychiatry* **2022**, *12*, 108. [[CrossRef](#)] [[PubMed](#)]
26. Speed, M.S.; Jepsen, O.H.; Borglum, A.D.; Speed, D.; Ostergaard, S.D. Investigating the association between body fat and depression via Mendelian randomization. *Transl. Psychiatry* **2019**, *9*, 184. [[CrossRef](#)]
27. Liao, S.-F.; Su, C.-Y.; Su, M.-H.; Chen, C.-Y.; Chen, C.-Y.; Lin, Y.-F.; Pan, Y.-J.; Hsiao, P.-C.; Chen, P.-C.; Huang, Y.-T.; et al. Association of polygenic risks, depression, and obesity-related traits in Taiwan Biobank. *J. Affect. Disord.* **2023**, *320*, 397–403. [[CrossRef](#)]
28. Gonzalez, J.R.; Ruiz-Arenas, C.; Caceres, A.; Moran, I.; Lopez-Sanchez, M.; Alonso, L.; Guindo-Martinez, M.; Mercader, J.M.; Esko, T.; Torrents, D.; et al. Polymorphic inversions underlie the shared genetic susceptibility of obesity-related diseases. *Am. J. Hum. Genet.* **2020**, *106*, 846–858. [[CrossRef](#)]
29. Milaneschi, Y.; Lamers, F.; Peyrot, W.J.; Baune, B.T.; Breen, G.; Dehghan, A.; Forstner, A.J.; Grabe, H.J.; Homuth, G.; Kan, C.; et al. Genetic association of major depression with atypical features and obesity-related immunometabolic dysregulations. *JAMA Psychiatry* **2017**, *74*, 1214–1225. [[CrossRef](#)]

30. Pistis, G.; Milaneschi, Y.; Vandeley, C.L.; Lasserre, A.M.; Penninx, B.W.J.H.; Lamers, F.; Boomsma, D.I.; Hottenga, J.-J.; Marques-Vidal, P.; Vollenweider, P.; et al. Obesity and atypical depression symptoms: Findings from Mendelian randomization in two European cohorts. *Transl. Psychiatry* **2021**, *11*, 96. [\[CrossRef\]](#)
31. Amare, A.T.; Schubert, K.O.; Tekola-Ayele, F.; Hsu, Y.-H.; Sangkuhl, K.; Jenkins, G.; Whaley, R.M.; Barman, P.; Batzler, A.; Altman, R.B.; et al. The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. *J. Neural Transm.* **2019**, *126*, 35–45. [\[CrossRef\]](#)
32. Hartwig, F.P.; Bowden, J.; de Mola, C.L.; Tovo-Rodrigues, L.; Smith, G.D.; Horta, B.L. Body mass index and psychiatric disorders: A Mendelian randomization study. *Sci. Rep.* **2016**, *6*, 32730. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Docherty, A.R. Leveraging psychiatric and medical genetics to understand comorbid depression and obesity. *Br. J. Psychiatry* **2017**, *211*, 61–62. [\[CrossRef\]](#)
34. Tricco, A.C.; Lillie, E.; Zarin, W.; Colquhoun, H.; Levac, D.; Moher, D.; Peters, M.D.; Horsley, T.; Weeks, L. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. *Ann. Intern. Med.* **2018**, *169*, 467–473. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Gharipour, M.; Barekatain, M.; Sung, J.; Emami, N.; Sadeghian, L.; Dianatkhah, M.; Sarrafzadegan, N.; Jahanfar, S. The epigenetic overlap between obesity and mood disorders: A systematic review. *Int. J. Mol. Sci.* **2020**, *21*, 6758. [\[CrossRef\]](#)
36. Sohani, Z.N.; Meyre, D.; de Souza, R.J.; Joseph, P.G.; Gandhi, M.; Dennis, B.B.; Norman, G.; Anand, S.S. Assessing the quality of published genetic association studies in meta-analyses: The quality of genetic studies (Q-Genie) tool. *BMC Genet.* **2015**, *16*, 50. [\[CrossRef\]](#)
37. Comings, D.E.; Comings, B.G.; Muhleman, D.; Dietz, G.; Shahbahrami, B.; Tast, D.; Knell, E.; Kocsis, P.; Baumgarten, R.; Kovacs, B.W. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. *JAMA* **1991**, *266*, 1793–1800. [\[CrossRef\]](#)
38. Comings, D.E.; Gade, R.; MacMurray, J.P.; Muhleman, D.; Peters, W.R. Genetic variants of the human obesity (OB) gene: Association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene. *Mol. Psychiatry* **1996**, *1*, 325–335.
39. Ejchel, T.F.; Araujo, L.M.Q.; Ramos, L.R.; Cendoroglo, M.S.; de Smith, M.A.C. Association of the apolipoprotein A-IV: 360 Gln/His polymorphism with cerebrovascular disease, obesity, and depression in a Brazilian elderly population. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **2005**, *135B*, 65–68. [\[CrossRef\]](#)
40. Chen, E.S.; Cendoroglo, M.S.; Ramos, L.R.; Araujo, L.M.Q.; Carvalheira, G.M.G.; de Labio, R.W.; Burbano, R.R.; Payao, S.L.M.; de Smith, M.A.C. APO A-V -113T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population. *Clin. Chem. Lab. Med.* **2006**, *44*, 32–36. [\[CrossRef\]](#)
41. Krishnamurthy, P.; Romagni, P.; Torvik, S.; Gold, P.W.; Charney, D.S.; Detera-Wadleigh, S.; Cizza, G.; P.O.W.E.R. Study Group. Glucocorticoid receptor gene polymorphisms in premenopausal women with major depression. *Comparative Study Horm. Metab. Res.* **2008**, *40*, 194–198. [\[CrossRef\]](#)
42. Spalova, J.; Zamrazilova, H.; Vcelak, J.; Vankova, M.; Lukasova, P.; Hill, M.; Hlatava, K.; Sramkova, P.; Fried, M.; Aldhoon, B.; et al. Neuromedin beta: P73T polymorphism in overweight and obese subjects. *Physiol. Res.* **2008**, *57*, S39–S48. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Fuemmeler, B.F.; Agurs-Collins, T.; McClermon, F.J.; Kollins, S.H.; Garrett, M.E.; Ashley-Koch, A.E. Interactions between genotype and depressive symptoms on obesity. *Behav. Genet.* **2009**, *39*, 296–305. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Kivimaki, M.; Jokela, M.; Hamer, M.; Geddes, J.; Ebmeier, K.; Kumari, M.; Singh-Manoux, A.; Hingorani, A.; Batty, D.G. Examining overweight and obesity as risk factors for common mental disorders using fat mass and obesity-associated (FTO) genotype-instrumented analysis: The Whitehall II study, 1985–2004. *Am. J. Epidemiol.* **2011**, *173*, 421–429. [\[CrossRef\]](#)
45. Rivera, M.; Cohen-Woods, S.; Kapur, K.; Breen, G.; Ng, M.Y.; Butler, A.W.; Craddock, N.; Gill, M.; Korszun, A.; Maier, W.; et al. Depressive disorder moderates the effect of the FTO gene on body mass index. *Mol. Psychiatry* **2012**, *17*, 604–611. [\[CrossRef\]](#) [\[PubMed\]](#)
46. Samaan, Z.; Anand, S.; Zhang, X.; Desai, D.; Rivera, M.; Pare, G.; Thabane, L.; Xie, C.; Gerstein, H.; Engert, J.C.; et al. The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. *Mol. Psychiatry* **2013**, *18*, 1281–1286. [\[CrossRef\]](#) [\[PubMed\]](#)
47. Beydoun, M.A.; Nalls, M.A.; Canas, J.A.; Evans, M.K.; Zonderman, A.B. Gene polymorphisms and gene scores linked to low serum carotenoid status and their associations with metabolic disturbance and depressive symptoms in African-American adults. *Br. J. Nutr.* **2014**, *112*, 992–1003. [\[CrossRef\]](#)
48. Harbron, J.; van der Merwe, L.; Zaahl, M.G.; Kotze, M.J.; Senekal, M. Fat mass and obesity-associated (FTO) gene polymorphisms are associated with physical activity, food intake, eating behaviors, psychological health, and modeled change in body mass index in overweight / obese Caucasian adults. *Nutrients* **2014**, *6*, 3130–3152. [\[CrossRef\]](#)
49. Bielinski, M.; Tomaszewska, M.; Jaracz, M.; Pulkowska-Ulfig, J.; Dlugosz, D.; Sikora, M.; Tretyn, A.; Kaminska, A.; Junik, R.; Borkowska, A. The polymorphisms in serotonin-related genes (5-HT2A and SERT) and the prevalence of depressive symptoms in obese patients. *Neurosci. Lett.* **2015**, *586*, 31–35. [\[CrossRef\]](#)
50. Borkowska, A.; Bielinski, M.; Szczesny, W.; Szwed, K.; Tomaszewska, M.; Kalwa, A.; Lesiewska, N.; Junik, R.; Golebiewski, M.; Sikora, M.; et al. Effect of the 5-HTTLPR polymorphism on affective temperament, depression and body mass index in obesity. *J. Affect. Disord.* **2015**, *184*, 193–197. [\[CrossRef\]](#)
51. Delacretaz, A.; Preisig, M.; Vandenbergh, F.; Morgui, N.S.; Quteineh, L.; Choong, E.; Gholam-Rezaee, M.; Kutalik, Z.; Magistretti, P.; Aubry, J.-M.; et al. Influence of MCHR2 and MCHR2-AS1 genetic polymorphisms on body mass index in psychiatric patients and in population-based subjects with present or past atypical depression. *PLoS ONE* **2015**, *10*, e0139155. [\[CrossRef\]](#)

52. McCaffery, J.M.; Papandonatos, G.D.; Faulconbridge, L.F.; Erar, B.; Peter, I.; Wagenknecht, L.E.; Pajewski, N.M.; Anderson, A.; Wadden, T.A.; Wing, R.R. Look AHEAD Research Group. Genetic predictors of depressive symptoms in the Look AHEAD trial. *Psychosom. Med.* **2015**, *77*, 982–992. [\[CrossRef\]](#) [\[PubMed\]](#)
53. Samaan, Z.; Lee, Y.K.; Gerstein, H.C.; Engert, J.C.; Bosch, J.; Mohan, V.; Diaz, R.; Yusuf, S.; Anand, S.S.; Meyre, D.; et al. Obesity genes and risk of major depressive disorder in a multiethnic population: A cross-sectional study. *J. Clin. Psychiatry* **2015**, *76*, e1611–e1618. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Yilmaz, Z.; Davis, C.; Loxton, N.J.; Kaplan, A.S.; Levitan, R.D.; Carter, J.C.; Kennedy, J.L. Association between MC4R rs17782313 polymorphism and overeating behaviours. *Int. J. Obes.* **2015**, *39*, 114–120. [\[CrossRef\]](#) [\[PubMed\]](#)
55. Quteineh, L.; Preisig, M.; Rivera, M.; Milaneschi, Y.; Castela, E.; Gholam-Razee, M.; Vandenberghe, F.; Saigi-Morgui, N.; Delacretaz, A.; Cardinaux, J.-R.; et al. Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression. *J. Affect. Disord.* **2016**, *198*, 43–49. [\[CrossRef\]](#)
56. Bielinski, M.; Jaracz, M.; Lesiewska, N.; Tomaszewska, M.; Sikora, M.; Junik, R.; Kaminska, A.; Tretyn, A.; Borkowska, A. Association between COMT Val158Met and DAT1 polymorphisms and depressive symptoms in the obese population. *Neuropsychiatr. Dis. Treat.* **2017**, *13*, 2221–2229. [\[CrossRef\]](#)
57. Hellgren, C.; Comasco, E.; Skalkidou, A.; Sundstrom-Poromaa, I. Allopregnanolone levels and depressive symptoms during pregnancy in relation to single nucleotide polymorphisms in the allopregnanolone synthetic pathway. *Horm. Behav.* **2017**, *94*, 106–113. [\[CrossRef\]](#)
58. Rivera, M.; Locke, A.E.; Corre, T.; Czamara, D.; Wolf, C.; Ching-Lopez, A.; Milaneschi, Y.; Kloiber, S.; Cohen-Woods, S.; Rucker, J.; et al. Interaction between the FTO gene, body mass index and depression: Meta-analysis of 13701 individuals. *Br. J. Psychiatry* **2017**, *211*, 70–76. [\[CrossRef\]](#)
59. Schepers, R.; and Markus, C.R. The interaction between 5-HTTLPR genotype and ruminative thinking on BMI. *Br. J. Nutr.* **2017**, *118*, 629–637. [\[CrossRef\]](#)
60. Treutlein, J.; Strohmaier, J.; Frank, J.; Witt, S.H.; Rietschel, L.; Forstner, A.J.; Lang, M.; Degenhardt, F.; Dukal, H.; Herms, S.; et al. Association between neuropeptide Y receptor Y2 promoter variant rs6857715 and major depressive disorder. *Psychiatr. Genet.* **2017**, *27*, 34–37. [\[CrossRef\]](#)
61. Brummett, B.H.; Babyak, M.A.; Singh, A.; Hauser, E.R.; Jiang, R.; Huffman, K.M.; Kraus, W.E.; Shah, S.H.; Siegler, I.C.; Williams, R.B. Lack of association of a functional polymorphism in the serotonin receptor gene with body mass index and depressive symptoms in a large meta-analysis of population based studies. *Front. Genet.* **2018**, *9*, 423. [\[CrossRef\]](#)
62. Hay, R.; Cullen, B.; Graham, N.; Lyall, D.M.; Aman, A.; Pell, J.P.; Ward, J.; Smith, D.J.; Strawbridge, R.J. Genetic analysis of the PCSK9 locus in psychological, psychiatric, metabolic and cardiovascular traits in UK Biobank. *Eur. J. Hum. Genet.* **2022**, *30*, 1380–1390. [\[CrossRef\]](#) [\[PubMed\]](#)
63. He, Y.; Brouwers, B.; Liu, H.; Liu, H.; Lawler, K.; de Oliveira, E.M.; Lee, D.-K.; Yang, Y.; Cox, A.R.; Keogh, J.M.; et al. Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior. *Nat. Med.* **2022**, *28*, 2537–2546. [\[CrossRef\]](#) [\[PubMed\]](#)
64. Rahati, S.; Qorbani, M.; Naghavi, A.; Pishva, H. Association and interaction of the MC4R rs17782313 polymorphism with plasma ghrelin, GLP-1, cortisol, food intake and eating behaviors in overweight/obese Iranian adults. *BMC Endocr. Disord.* **2022**, *22*, 234. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Gerken, T.; Girard, C.A.; Tung, Y.-C.L.; Webby, C.J.; Saudek, V.; Hewitson, K.S.; Yeo, G.S.H.; McDonough, M.A.; Cunliffe, S.; McNeill, L.A.; et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. *Science* **2007**, *318*, 1469–1472. [\[CrossRef\]](#) [\[PubMed\]](#)
66. Speakman, J.R. The ‘fat mass and obesity related’ (FTO) gene: Mechanisms of impact on obesity and energy balance. *Curr. Obes. Rep.* **2015**, *4*, 73–91. [\[CrossRef\]](#)
67. Hainer, V.; Hainerova, I.A.; Kunesova, M.; Braunerova, R.T.; Zamrazilova, H.; Bendlova, B. Melanocortin pathways: Suppressed and stimulated melanocortin-4 receptor (MC4R). *Physiol. Res.* **2020**, *69*, S245–S254. [\[CrossRef\]](#)
68. Shende, P.; Desai, D. Physiological and therapeutic roles of neuropeptide Y on biological functions. *Adv. Exp. Med. Biol.* **2020**, *1237*, 37–47. [\[CrossRef\]](#)
69. Diniz, G.B.; Bittencourt, J.G. The melanin-concentrating hormone (MCH) system: A tale of two peptides. *Front. Neurosci.* **2019**, *13*, 1280. [\[CrossRef\]](#)
70. Peng, Q.; Yan, H.; Wen, Y.; Lai, C.; Shi, L. Association between NR3C1 rs41423247 polymorphism and depression: A PRISMA-compliant meta-analysis. *Medicine* **2018**, *97*, e12541. [\[CrossRef\]](#)
71. Zhang, L.; Yuan, L.-H.; Xiao, Y.; Lu, M.-Y.; Zhang, L.-J.; Wang, Y. Association of leptin gene -2548 G/A polymorphism with obesity: A meta-analysis. *Ann. Nutr. Metab.* **2014**, *64*, 127–136. [\[CrossRef\]](#)
72. Hung, C.-F.; Breen, G.; Czamara, D.; Corre, T.; Wolf, C.; Kloiber, S.; Bergmann, S.; Craddock, N.; Gill, M.; Holsboer, F.; et al. A genetic risk score combining 32 SNPs is associated with body mass index and improves obesity prediction in people with major depressive disorder. *BMC Med.* **2015**, *13*, 86. [\[CrossRef\]](#)
73. Anguita-Ruiz, A.; Zarza-Rebollo, J.A.; Perez-Gutierrez, A.M.; Molina, E.; Guterrez, B.; Bellon, J.A.; Moreno-Peral, P.; Conejo-Ceron, S.; Aiarsaguena, J.M.; Ballesta-Rodriguez, M.I.; et al. Body mass index interacts with a genetic risk score for depression increasing the risk of the disease in high-susceptibility individuals. *Transl. Psychiatry* **2022**, *12*, 30. [\[CrossRef\]](#) [\[PubMed\]](#)

74. Jokela, M.; Elovainio, M.; Keltikangas-Jarvinen, L.; Batty, G.D.; Hintsanen, M.; Seppala, I.; Kahonen, M.; Viikari, J.S.; Raitakari, O.T.; Lehtimäki, T.; et al. Body mass index and depressive symptoms: Instrumental-variables regression with genetic risk score. *Genes Brain Behav.* **2012**, *11*, 942–948. [\[CrossRef\]](#) [\[PubMed\]](#)
75. Mulugeta, A.; Vimalaswaran, K.S.; Dickson, C.; Hypponen, E. Depression increases the genetic susceptibility to high body mass index: Evidence from UK Biobank. *Depress. Anxiety* **2019**, *36*, 1154–1162. [\[CrossRef\]](#) [\[PubMed\]](#)
76. Avinun, R.; Hariri, A.R. A polygenic score for body mass index is associated with depressive symptoms via early life stress: Evidence for gene-environment correlation. *J. Psychiatr. Res.* **2019**, *118*, 9–13. [\[CrossRef\]](#)
77. Khera, R.; Murad, M.H.; Chandar, A.K.; Dulai, P.S.; Wang, Z.; Prokop, L.J.; Loomba, R.; Camilleri, M.; Singh, S. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. *JAMA* **2016**, *315*, 2424–2434. [\[CrossRef\]](#)
78. Serretti, A.; Mandelli, L. Antidepressants and body weight: A comprehensive review and meta-analysis. *J. Clin. Psychiatry* **2010**, *71*, 1259–1272. [\[CrossRef\]](#)
79. Zhou, L.-L.; Xu, H.; Huang, Y.; Yang, C.-G. Targeting the RNA demethylase FTO for cancer therapy. *RSC Chem. Biol.* **2021**, *2*, 1352. [\[CrossRef\]](#)
80. Huff, S.; Kummetha, I.R.; Zhang, L.; Wang, L.; Bray, W.; Yin, J.; Kelley, V.; Wang, Y.; Rana, T.M. Rational design and optimization of m6A-RNA demethylase FTO inhibitors as anticancer agents. *J. Med. Chem.* **2022**, *65*, 10920–10937. [\[CrossRef\]](#)
81. Spana, C.; Jordan, R.; Fischkoff, S. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. *Diabetes Obes. Metab.* **2022**, *24*, 1084–1093. [\[CrossRef\]](#)
82. Pressley, H.; Cornelio, C.K.; Adams, E.N. Setmelanotide: A novel targeted treatment for monogenic obesity. *J. Pharm. Technol.* **2022**, *38*, 368–373. [\[CrossRef\]](#) [\[PubMed\]](#)
83. Haqq, A.M.; Chung, W.K.; Dollfus, H.; Haws, R.M.; Martos-Moreno, G.A.; Poitou, C.; Yanovski, J.A.; Mittleman, R.S.; Yuan, G.; Forsythe, E.; et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial with an open label period. *Lancet Diabetes Endocrinol.* **2022**, *10*, 859–868. [\[CrossRef\]](#) [\[PubMed\]](#)
84. Serova, L.I.; Laukova, M.; Alaluf, L.G.; Sabban, E.L. Intranasal infusion of melanocortin receptor four (MC4R) antagonist to rats ameliorates development of depression and anxiety related symptoms induced by single prolonged stress. *Behav. Brain Res.* **2013**, *250*, 139–147. [\[CrossRef\]](#)
85. Sabban, E.L.; Serova, L.I.; Alaluf, L.G.; Laukova, M.; Peddu, C. Comparative effects of intranasal neuropeptide Y and HS014 in preventing anxiety and depressive-like behavior elicited by single prolonged stress. *Behav. Brain Res.* **2015**, *295*, 9–16. [\[CrossRef\]](#) [\[PubMed\]](#)
86. Saleh, N.; Kleinau, G.; Heyder, N.; Clark, T.; Hildebrand, P.W.; Scheerer, P. Binding, thermodynamics, and selectivity of a non-peptide antagonist to the melanocortin-4 receptor. *Front. Pharmacol.* **2018**, *9*, 560. [\[CrossRef\]](#)
87. Gehlert, D.R.; Rasmussen, K.; Shaw, J.; Li, X.; Aradyfio, P.; Craft, L.; Coskun, T.; Zhang, H.Y.; Chen, Y.; Witkin, J.M. Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. *J. Pharmacol. Exp. Ther.* **2009**, *329*, 429–438. [\[CrossRef\]](#)
88. Chen, X.; Mihalic, J.; Fan, P.; Liang, L.; Lindstrom, M.; Wong, S.; Ye, Q.; Fu, Y.; Jaen, J.; Chen, J.-L.; et al. Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 363–366. [\[CrossRef\]](#)
89. Domin, H. Neuropeptide Y Y2 and Y5 receptors as potential targets for neuroprotective and antidepressant therapies: Evidence from preclinical studies. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2021**, *111*, 110349. [\[CrossRef\]](#)
90. Merkel, R.; Moreno, A.; Zhang, Y.; Herman, R.; Ben Nathan, J.; Zeb, S.; Rahematpura, S.; Stecyk, K.; Milliken, B.T.; Hayes, M.R.; et al. A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide receptors and neuropeptide Y2 receptors. *Neurosci. Biobehav. Rev.* **2021**, *131*, 1169–1179. [\[CrossRef\]](#)
91. Anam, M.; Maharjan, S.; Amjad, Z.; Abaza, A.; Vasavada, A.M.; Sadhu, A.; Valencia, C.; Fatima, H.; Nwankwo, I. Efficacy of semaglutide in treating obesity: A systematic review of randomized controlled trials. *Cureus* **2022**, *14*, e32610. [\[CrossRef\]](#)
92. Clark, R.D. Glucocorticoid receptor antagonists. *Curr. Top. Med. Chem.* **2008**, *8*, 813–838. [\[CrossRef\]](#)
93. Morice, C.; Baker, D.G.; Patel, M.M.; Nolen, T.L.; Nowak, K.; Hirsch, S.; Kosten, T.R.; Verrico, C.D. A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers. *Sci. Rep.* **2021**, *11*, 9876. [\[CrossRef\]](#)
94. Kroon, J.; Koorneef, L.L.; van den Heuvel, J.K.; Verzijl, C.R.C.; van de Velde, N.M.; Mol, I.M.; Sips, H.C.M.; Hunt, H.; Rensen, P.C.N.; Meijer, O.C. Selective glucocorticoid receptor antagonist CORT125281 activates brown adipose tissue and alters lipid distribution in male mice. *Endocrinology* **2018**, *159*, 535–546. [\[CrossRef\]](#) [\[PubMed\]](#)
95. Dwyer, J.B.; Aftab, A.; Radhakrishnan, R.; Widge, A.; Rodriguez, C.I.; Carpenter, L.L.; Nemeroff, C.B.; McDonald, W.M.; Kalin, N.H.; APA Council of Research Task Force on Novel Biomarkers and Treatments. Hormonal treatments for major depressive disorder: State of the art. *Am. J. Psychiatry* **2020**, *177*, 686–705. [\[CrossRef\]](#) [\[PubMed\]](#)
96. Zhang, Y.; Suo, Y.; Yang, L.; Zhang, X.; Yu, Q.; Zeng, M.; Zhang, W.; Jiang, X.; Wang, Y. Effect of PCSK9 inhibitor on blood lipid levels in patients with high and very-high CVD risk: A systematic review and meta-analysis. *Cardiol. Res. Pract.* **2022**, *2022*, 8729003. [\[CrossRef\]](#)

97. Deshycka, R.; Sudaryo, V.; Huang, N.-J.; Xie, Y.; Smeding, L.Y.; Choi, M.K.; Ploegh, H.L.; Lodish, H.F.; Pishesha, N. Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity. *PLoS ONE* **2021**, *16*, e0259353. [[CrossRef](#)]
98. Alghamdi, J.; Matou-Nasri, S.; Alghamdi, F.; Alghamdi, S.; Alfadhel, M.; Padmanabham, S. Risk of neuropsychiatric adverse effects of lipid-lowering drugs: A Mendelian randomization study. *Int. J. Neuropsychopharmacol.* **2018**, *21*, 1067–1075. [[CrossRef](#)]
99. Kljun, J.; Pavlic, R.; Hafner, E.; Lipek, T.; Moreno-Da Silva, S.; Tic, P.; Turel, I.; Budefeld, T.; Stojan, J.; Rizner, T.L. Ruthenium complexes show potent inhibition of AKR1C1, AKR1C2, and AKR1C3 enzymes and anti-proliferative action against chemoresistant ovarian cancer cell line. *Front. Pharmacol.* **2022**, *13*, 920379. [[CrossRef](#)]
100. Lim, F.Q.; Chan, A.S.-Y.; Yokomori, R.; Huang, X.Z.; Theardy, M.S.; Yeoh, A.E.J.; Tan, S.H.; Sanda, T. Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia. *Haematologica* **2023**, *108*, 367–381. [[CrossRef](#)]
101. Zhong, T.; Zhang, H.; Duan, X.; Hu, J.; Wang, L.; Li, L.; Zhang, H.; Niu, L. Anti-obesity effect of radix *Angelica sinensis* and candidate causative genes in transcriptome analyses of adipose tissues in high-fat diet-induced mice. *Gene* **2017**, *599*, 92–98. [[CrossRef](#)]
102. Huang, L.; Zhang, J.; Zhu, X.; Mi, X.; Li, Q.; Gao, J.; Zhou, J.; Zhou, J.; Liu, X.-M. The phytochemical rhein mediates M6A-independent suppression of adipocyte differentiation. *Front. Nutr.* **2021**, *8*, 756803. [[CrossRef](#)]
103. Ezzat, S.M.; El Bishbishy, M.H.; Aborehab, N.M.; Salama, M.M.; Hasheesh, A.; Motaal, A.A.; Rashad, H.; Metwally, F.M. Upregulation of MC4R and PPAR- α expression mediates the anti-obesity activity of *Moringa oleifera* Lam. in high-fat diet-induced obesity in rats. *J. Ethnopharmacol.* **2020**, *251*, 112541. [[CrossRef](#)] [[PubMed](#)]
104. Morita, S.; Sakamaki, A.; Koyama, K.; Shibata, O.; Owaki, T.; Oda, C.; Kimura, A.; Nakaya, T.; Ohbuchi, K.; Nahata, M.; et al. Daisaikoto improves fatty liver and obesity in melanocortin-4 receptor gene-deficient mice via the activation of brown adipose tissue. *Sci. Rep.* **2022**, *12*, 10105. [[CrossRef](#)] [[PubMed](#)]
105. Zhang, Q.-H.; Cui, X.-Y.; Wang, D.; Jin, Y.; Guan, Y.-X. Anti-obesity effect of escin: A study on high-fat diet-induced obese mice. *Eur. Rev. Med. Pharmacol. Sci.* **2022**, *26*, 7797–7812. [[CrossRef](#)]
106. Zhao, Q.; Pan, W.; Shi, H.; Qi, F.; Liu, Y.; Yang, T.; Si, H.; Si, G. Network pharmacology and molecular docking analysis on the mechanism of Baihe Zhimu decoction in the treatment of postpartum depression. *Medicine* **2022**, *101*, 43. [[CrossRef](#)]
107. Chang, Z.; He, L.-J.; Tian, D.-F.; Gao, Q.; Ling, J.-F.; Wang, Y.-C.; Han, Z.-Y.; Guo, R.-J. Therapeutic targets and mechanism of Xingpi Jieyu decoction in depression: A network pharmacology study. *Evid. Based Complement. Alternat. Med.* **2021**, *2021*, 5516525. [[CrossRef](#)]
108. Nguyen, H.D.; Kim, M.-S. The protective effects of curcumin on depression: Genes, transcription factors, and microRNAs involved. *J. Affect. Disord.* **2022**, *319*, 526–537. [[CrossRef](#)]
109. Phung, H.M.; Jang, D.; Trinh, T.A.; Lee, D.; Nguyen, Q.N.; Kim, C.-E.; Kang, K.S. Regulation of appetite-related neuropeptides by *Panax ginseng*: A novel approach for obesity treatment. *J. Ginseng Res.* **2022**, *46*, 609–619. [[CrossRef](#)] [[PubMed](#)]
110. Ashmawy, A.I.; El-Abhar, H.S.; Abdallah, D.M.; Ali, M.A. Chloroquine modulates the sulforaphane anti-obesity mechanisms in a high-fat diet model: Role of JAK-2/STAT-3/SOCS-3 pathway. *Eur. J. Pharmacol.* **2022**, *927*, 175066. [[CrossRef](#)]
111. Song, J.; Kim, J.; Park, H.J.; Kim, H. Anti-obesity effects of a *Prunus persica* and *Nelumbo nucifera* mixture in mice fed a high-fat diet. *Nutrients* **2020**, *12*, 3392. [[CrossRef](#)]
112. Orabi, S.H.; Al-Sabbagh, E.S.; Khalifa, H.K.; Mohamed, M.A.E.; Elhamouly, M.; Gad-Allah, S.M.; Abdel-Daim, M.M.; Abd Eldaim, M.A. *Commiphora myrrha* resin alcoholic extract ameliorates high fat diet induced obesity via regulation of UCP1 and adiponectin proteins expression in rats. *Nutrients* **2020**, *12*, 803. [[CrossRef](#)]
113. Lin, Z.; Li, F.; Zhang, Y.; Tan, X.; Luo, P.; Liu, H. Analysis of asthaxanthin molecular targets based on network pharmacological strategies. *J. Food Biochem.* **2021**, *45*, e13717. [[CrossRef](#)] [[PubMed](#)]
114. Xie, R.-F.; Song, Z.-Y.; Xu-Shao, L.-Y.; Huang, J.-G.; Zhao, T.; Yang, Z. The mechanism of Bai He Gu Jin Tiang against non-small cell lung cancer revealed by network pharmacology and molecular docking. *Medicine* **2022**, *101*, e32555. [[CrossRef](#)] [[PubMed](#)]
115. Pel, P.; Kim, Y.-M.; Kim, H.J.; Nhoek, P.; An, C.-Y.; Son, M.-G.; Won, H.; Lee, S.E.; Lee, J.; Kim, H.W.; et al. Isocoumarins and benzoquinones with their proprotein convertase subtilisin/kexin type 9 expression inhibitory activities from dried roots of *Lysimachia vulgaris*. *ACS Omega* **2022**, *7*, 47296–47305. [[CrossRef](#)]
116. Mannino, G.; Iovino, P.; Lauria, A.; Genova, T.; Asteggiano, A.; Notarbartolo, M.; Porcu, A.; Serio, G.; Chinigo, G.; Occhipinti, A.; et al. Bioactive triterpenes of *Protium heptaphyllum* gum resin extract display cholesterol-lowering potential. *Int. J. Mol. Sci.* **2021**, *22*, 2264. [[CrossRef](#)]
117. Nhoek, P.; Chae, H.-S.; Kim, Y.-M.; Pel, P.; Huh, J.; Kim, H.-W.; Choi, Y.H.; Lee, K.; Chin, Y.-W. Sesquiterpenoids from the aerial parts of *Salvia plebeia* with inhibitory activities on proprotein convertase subtilisin/kexin type 9 expression. *J. Nat. Prod.* **2021**, *84*, 220–229. [[CrossRef](#)]
118. Matschke, V.; Piccini, I.; Schubert, J.; Wrobel, E.; Lang, F.; Matschke, J.; Amedonu, E.; Meuth, S.G.; Strunker, T.; Strutz-Seeböhm, N.; et al. The natural plant product rottlerin activates KV7.1/KCNE1 channels. *Cell Physiol. Biochem.* **2016**, *40*, 1549–1558. [[CrossRef](#)]
119. Manville, R.M.; Abbott, G.W. Cilantro leaf harbors a potent potassium channel-activating anticonvulsant. *FASEB J.* **2019**, *33*, 11349–11363. [[CrossRef](#)] [[PubMed](#)]

120. Choi, S.-H.; Lee, B.-H.; Kim, H.-J.; Jung, S.-W.; Kim, H.-S.; Shin, H.-C.; Lee, J.-H.; Kim, H.-C.; Rhim, H.; Hwang, S.-H.; et al. Ginseng gintonin activates the human cardiac delayed rectifier K⁺ channel: Involvement of Ca²⁺/calmodulin binding sites. *Mol. Cells* **2014**, *37*, 656–663. [[CrossRef](#)]
121. Koochakpoor, G.; Hosseini-Esfahani, F.; Daneshpour, M.S.; Hosseini, S.A.; Mirmiran, P. Effect of interactions of polymorphisms in the melanocortin-4 receptor gene with dietary factors on the risk of obesity and type 2 diabetes: A systematic review. *Diabet. Med.* **2016**, *33*, 1026–1034. [[CrossRef](#)]
122. Normann, C.; Buttenschon, H.N. Gene-environment interactions between HPA-axis genes and childhood maltreatment in depression: A systematic review. *Acta Neuropsychiatr.* **2020**, *32*, 111–121. [[CrossRef](#)] [[PubMed](#)]
123. Gonzalez-Muniesa, P.; Martinez-Gonzalez, M.-A.; Hu, F.B.; Despres, J.-P.; Matsuzawa, Y.; Loos, R.J.F.; Moreno, L.A.; Bray, G.A.; Martinez, J.A. Obesity. *Nat. Rev. Dis. Primers* **2017**, *3*, 17034. [[CrossRef](#)] [[PubMed](#)]
124. Jones, C.; Nemeroff, C.B. Precision psychiatry: Biomarker-guided tailored therapy for effective treatment and prevention in major depression. *Adv. Exp. Med. Biol.* **2021**, *1305*, 535–563. [[CrossRef](#)]
125. Konuma, T.; Okada, Y. Statistical genetics and polygenic risk score for precision medicine. *Inflamm. Regen.* **2021**, *41*, 18. [[CrossRef](#)]
126. Matsuo, T.; Nakata, Y.; Hotta, K.; Tanaka, K. The FTO genotype as a useful predictor of body weight maintenance: Initial data from a 5-year follow-up study. *Metabolism* **2014**, *63*, 912–917. [[CrossRef](#)]
127. De Vincentis, A.; Pedone, C.; Vespasiani-Gentilucci, U.; Picardi, A.; Derosa, G.; Maffioli, P.; Sahebkar, A. Effect of sibutramine on plasma C-reactive protein, leptin and adiponectin concentrations: A systematic review and meta-analysis of randomized controlled trials. *Curr. Pharm. Des.* **2017**, *23*, 870–878. [[CrossRef](#)] [[PubMed](#)]
128. Liu, S.; Xiu, J.; Zhu, C.; Meng, K.; Li, C.; Han, R.; Du, T.; Li, L.; Xu, L.; Liu, R.; et al. Fat mass and obesity-associated protein regulates RNA methylation associated with depression-like behavior in mice. *Nat. Commun.* **2021**, *12*, 6937. [[CrossRef](#)]
129. Li, Y.; Chen, H.; Wang, J.; Wang, J.; Niu, X.; Wang, C.; Qin, D.; Li, F.; Wang, Y.; Xiong, J.; et al. Inflammation-activated C/EPB β mediates high-fat diet-induced depression-like behaviors in mice. *Front. Mol. Neurosci.* **2022**, *15*, 1068164. [[CrossRef](#)]
130. Yoo, A.; Joo, Y.; Cheon, Y.; Lee, S.J.; Lee, S. Neuronal growth regulator 1 promotes adipocyte lipid trafficking via interaction with CD36. *J. Lipid Res.* **2022**, *63*, 100221. [[CrossRef](#)]
131. Delgado, I.; Cusotto, S.; Anesi, A.; Dexpert, S.; Aubert, A.; Aouizerate, B.; Beau, C.; Forestier, D.; Ledaguenel, P.; Magne, E.; et al. Association between the indole pathway of tryptophan metabolism and subclinical depressive symptoms in obesity: A preliminary study. *Int. J. Obes.* **2022**, *46*, 885–888. [[CrossRef](#)]
132. Kurek, A.; Glombik, K.; Detka, J.; Basta-Kaim, A.; Kubera, M.; Lason, W.; Budziszewska, B. Regulators of glucocorticoid receptor function in an animal model of depression and obesity. *J. Neuroendocrinol.* **2018**, *30*, e12591. [[CrossRef](#)] [[PubMed](#)]
133. Glombik, K.; Detka, J.; Goralska, J.; Kurek, A.; Solnica, B.; Budziszewska, B. Brain metabolic alterations in rats showing depression-like and obesity phenotypes. *Neurotox. Res.* **2020**, *37*, 406–424. [[CrossRef](#)] [[PubMed](#)]
134. Spielmans, G.I.; Spence-Sing, T.; Parry, P. Duty to warn: Antidepressant black box suicidality warning is empirically justified. *Front. Psychiatry* **2020**, *11*, 18. [[CrossRef](#)] [[PubMed](#)]
135. Mead, E.; Atkinson, G.; Richter, B.; Metzendorf, M.-I.; Baur, L.; Finer, N.; Corpeleijn, E.; O'Malley, C.; Ells, L.J. Drug interventions for the treatment of obesity in children and adolescents. *Cochrane Database Syst. Rev.* **2016**, *11*, CD012436. [[CrossRef](#)]
136. Nelson, K.M.; Dahlin, J.L.; Bisson, J.; Graham, J.; Pauli, G.F.; Walters, M.A. Curcumin may (not) defy science. *ACS Med. Chem. Lett.* **2017**, *8*, 467–470. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.